After radical excision of a tumor in the maxillofacial area, functional and esthetic reconstruction is needed, including flap surgery. Among the many etiologies of flap failure, venous thrombosis is one of the most frequent. Heparin is used routinely in the effort to avoid development of venous thrombosis. In rare cases, heparin-induced thrombocytopenia (HIT) type II occurs due to exposure to heparin. Heparin attached to platelet factor 4 forms a PF4/heparin-immunoglobulin G immune complex on platelet surfaces. This complex activates platelets, which leads to multiple coagulation in venous and arterial blood. We report here on a rare occurrence of HIT type II following fibula free flap surgery.
Introduction
Heparin-induced thrombocytopenia (HIT) type II is defined as the formation of systemic thrombus accompanied by a more than 50% reduction of platelet count, with no other explanation than exposure to heparin [1] .
HIT is important in reconstruction due to the inevitable use of heparin in free flap surgery [2] . Thrombocytopenia due to HIT type II influences flap survival. Even small amounts of heparin, such as from irrigation or a catheter coating, can trigger HIT [3] . During a low-platelet period, vascular conditions can give rise to a thrombus, which can cause organ failure and finally death [4] .
There are two types of HIT. Type I HIT is momentary, occurring approximately four days after exposure to heparin. Minor thrombocytopenia springs up and is not associated with immunoglobulins. Type II HIT is mediated by immunoglobulin G (IgG) and manifests as a critical diminution in platelet count 4 to 14 days after exposure to heparin. Potentially fatal complications require immediate intervention [5] . However, this is unusual and rarely occurs. Eight days after the operation, congestion was seen on the skin portion of the free flap area. A Doppler test was performed immediately and blood flow through vessels was maintained. Daily lab tests showed a slight reduction of the platelet count. Eleven days after the operation, the platelet count fell to 26,000/μL ( Fig. 3 ). For evaluation of systemic thrombosis, an ultrasonography test was performed on the legs and arms, and a chest CT was taken, which showed pulmonary thromboembolism and partial pulmonary infarction. The 4 T's test indicated a more than 50% reduction in platelet count within 5 to 10 days after the operation and thrombus formation with no other remark- Heparin is used routinely for maintenance of blood flow and prevention of thrombosis. Its most common complication is bleeding. HIT type II is a rare disease compared to other complications, exposure of heparin constituting its predisposing factor. Although there is no bleeding tendency in HIT type 2, there is usually systemic coagulation. Smythe et al. [8] reported that the incidence of HIT type II is 0.2%. Warkentin et al. [9] reported that the incidence may increase to 1% in the context of major surgery. After the operation, damaged endothelial cells cause platelets and platelet factor 4 (PF4) to become more active, increasing the likelihood of HIT. Use of low molecular weight heparin (LMWH) decreases the incidence of HIT.
Case Report
HIT type II is associated with an immune reaction related to IgG, which binds to heparin and forms negatively charged antibodies against PF4. The antibodies bind with negatively charged PF4, forming a complex involved in platelet activation, coagulation, and endothelial activity. Platelet factor is accelerated by cross-linking of heparin-IgG/PF4 complex, which can lead to strong coagulation. Reduction of platelet count occurs 4 to 14 days after exposure to heparin, but can occur within as little as 24 hours [10] . Manifestations of anaphylactoid reaction include acute hypertension, dyspnea, fever, chills, chest pain, and tachycardia, with severe cases resulting in respiratory or cardiogenic arrest. In our case, the patient showed dyspnea seven days after the operation and re-entered the ICU.
Because of these risk factors, Warkentin [10] recommended that HIT type II patients should receive care in the ICU. Based on reported cases, approximately 4% to 5% of HIT type II patients are at risk of death [4] .
For prevention of HIT, unfractioned heparin (UFH) can be replaced by LMWH, which generally shows lower incidence of HIT than UFH. However, the risk of HIT remains with LMWH, which is more costly.
Although HIT is clearly dangerous, there is no viable replacement for heparin, drugs such as direct thrombin inhibitor (DTI) notwithstanding. Heparin, the most valuable anti-thrombotic drug, has the advantages of not going over liver and kidney and its anti-thrombotic effect can be easily reversed by protamine. In addition, DTI agents such as argatroban and lepirudin should be regulated using bleeding markers such as partial thromboplastin time value, complicated and laborious work, which can easily fail.
Most patients who receive heparin therapy are free of HIT.
For evaluation of flap survival, the clinician must perform an inspection for several signs. Detection of congestion and swelling, which is sometimes fatal to flap survival, is dependent on repeated color inspection, pressure test for perfusion, and ultrasonic Doppler test. If thrombosis accompanied by an abrupt decrease in platelet count is observed, the clinician should consider the possibility of HIT type II, whose conclusive diagnosis requires recovery of platelet count after discontinuing heparin. Other diagnostic methods for HIT type II are platelet serotonin-release assay, heparin induced platelet activation test, IgG-specific PF4-dependent enzyme immunoassays, and polyspecific enzyme immunoassays [11] . As these lab tests take considerable time, the clinician often reaches a diagnosis based on the clinical situation. In this case, these lab tests were not performed due to lack of assay facilities.
It is important that clinicians understand the following: when thrombosis is found, its cause must be determined.
Virchow's triad is useful in this respect. Virchow proposed that three elements can lead to development of thrombosis: stasis, changes in the vessel wall, and changes in the blood.
If there are no other reasons for thrombosis and platelet count starts to decrease, the 4 T's scoring system can be utilized [12] . If HIT type II is presumed, immediate consultation to a hematologist is necessary. Prognosis of HIT type II is dependent on early detection and early treatment. Five steps recommended for handling a diagnosis of HIT type II include stopping all heparin medication, consultation to a hematologist, use of another antithrombotic agent, imaging study for thrombosis, and study of antibodies [12] .
We used argatroban instead of heparin. After discontinuing heparin, the platelet count starts to increase. In treatment of HIT, additional heparin injection is not allowed, as this can cause massive coagulation followed by systemic thrombosis.
DeBois et al. [13] recommended at least two platelet counts per week when using heparin. American CHEST physicians' guidelines [6] recommend one platelet count per two days. As the operation can increase the incidence of HIT type II, we propose a daily platelet count check two weeks post-operatively. HIT type II usually starts 4 to 14 days after the operation.
HIT type II is a rare disease related to heparin exposure, which leads to coagulation disorder. Local or systemic coagulation may cause flap failure and other fatal complications. When flap congestion accompanied by an abrupt decrease in platelet count occurs for no particular reason, the clinician should consider HIT type II. Early diagnosis and treatment is essential.
